Innate Pharma (IPHA) Total Current Liabilities (2017 - 2025)

Innate Pharma (IPHA) has reported Total Current Liabilities for 9 consecutive years, with $41.7 million the latest figure, recorded in Q4 2025.

• Quarterly Total Current Liabilities rose 11.12% year-over-year to $41.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $41.7 million (up 11.12% YoY) and the FY2025 annual result came in at $41.7 million, up 11.12% from the prior year.
• Total Current Liabilities rose to $41.7 million in Q4 2025 per IPHA's latest filing, from $33.5 million in the prior quarter.
• Over the last five years, Total Current Liabilities for IPHA reached as high as $90.9 million in Q4 2021 and fell as low as $33.5 million in Q2 2025.
• A 5-year average of $51.4 million and a median of $44.3 million in 2023 frame the typical range for Total Current Liabilities.
• The largest YoY upside for Total Current Liabilities was 75.62% in 2021 against a maximum downside of 99.94% in 2021.
• Year by year, Total Current Liabilities stood at $90.9 million in 2021, then tumbled by 48.25% to $47.0 million in 2022, then slipped by 4.12% to $45.1 million in 2023, then fell by 16.79% to $37.5 million in 2024, then climbed by 11.12% to $41.7 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $41.7 million, $33.5 million, and $37.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.